- Home
- CASI vs GBIO Comparison
CASI vs GBIO Comparison
Compare CASI & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- GBIO
- Stock Information
- Founded
- CASI 1991
- GBIO 2016
- Country
- CASI China
- GBIO United States
- Employees
- CASI N/A
- GBIO N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- GBIO Health Care
- Exchange
- CASI Nasdaq
- GBIO Nasdaq
- Market Cap
- CASI 35.8M
- GBIO 29.5M
- IPO Year
- CASI 1996
- GBIO 2020
- Fundamental
- Price
- CASI $2.28
- GBIO $5.93
- Analyst Decision
- CASI Strong Buy
- GBIO Buy
- Analyst Count
- CASI 1
- GBIO 4
- Target Price
- CASI $4.00
- GBIO $10.67
- AVG Volume (30 Days)
- CASI 384.8K
- GBIO 85.8K
- Earning Date
- CASI 11-13-2025
- GBIO 11-05-2025
- Dividend Yield
- CASI N/A
- GBIO N/A
- EPS Growth
- CASI N/A
- GBIO N/A
- EPS
- CASI N/A
- GBIO N/A
- Revenue
- CASI $31,564,000.00
- GBIO $21,230,000.00
- Revenue This Year
- CASI N/A
- GBIO N/A
- Revenue Next Year
- CASI N/A
- GBIO N/A
- P/E Ratio
- CASI N/A
- GBIO N/A
- Revenue Growth
- CASI 36.64
- GBIO 61.15
- 52 Week Low
- CASI $1.09
- GBIO $3.00
- 52 Week High
- CASI $7.55
- GBIO $29.10
- Technical
- Relative Strength Index (RSI)
- CASI 55.66
- GBIO 54.01
- Support Level
- CASI $2.18
- GBIO $5.63
- Resistance Level
- CASI $2.49
- GBIO $6.25
- Average True Range (ATR)
- CASI 0.19
- GBIO 0.31
- MACD
- CASI -0.03
- GBIO -0.09
- Stochastic Oscillator
- CASI 33.33
- GBIO 36.78
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.